Description
Storage
Human IFN-α 2a Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/mL which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.
Source / Purification
Recombinant human IFN-α 2a was expressed in and is supplied in a lyophilized form.
Background
Interferons (IFNs) appear both locally and systematically early after viral infection and participate in limiting the spread of infection. They also affect cell differentiation, growth, surface antigen expression, and immunoregulation (1). There are three naturally occurring interferons: α, β, and γ. IFN-α is derived from lymphoblastic tissue and has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-α from both natural and synthetic genes binds to a common cell surface receptor and induces antiviral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-α induces rapid changes in Jak/Stat phosphorylation, which initiates the Jak/Stat signaling pathway (2). IFN-α signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (β and ε) (3). All IFN-α signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities. The human IFN-α 2 subvariants 2a and 2b differ by one or two amino acids at positions 23 and/or 34 of the mature protein (4). Pegylated forms of IFN-α 2 and recombinant IFN-α 2 protein are used clinically as standard treatments for anti-viral and anti-tumor therapies (5). IFN-α 2a and 2b proteins have also been shown to have implications in treating hepatitis C (6).
